Inventurus Knowledge Solutions Limited has informed the Exchange about Investor Presentation
IKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts more than Nifty Smallcap 250 and 1.5 pts more than its IT Enabled Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
IKS Health announced a strategic acquisition of US-listed TruBridge, Inc., a provider of integrated RCM (Revenue Cycle Management) and EHR (Electronic Health Record) solutions for small and rural US hospitals. The deal values TruBridge at $557M enterprise value ($427M equity + $130M net debt) and will be funded through ~$600M of debt at SOFR+275 bps, giving combined leverage of ~3x EBITDA. On a proforma FY2025 basis, the combined entity would have $698M revenue and $186M adjusted EBITDA (26% margin), with management stating the deal will be PAT and EPS accretive in FY27. IKS also unveiled an FY2030 vision targeting EBITDA of ~₹3,000 crore (vs ~₹1,000 crore LTM Dec 2025), implying aggressive scaling. The company highlighted a $575M cross-sell white space in TruBridge's client base and a $650M opportunity for TruCode, expecting close in Q2 FY27.
This is a significant debt-funded expansion that nearly doubles IKS's revenue base and gives it a foothold in the US hospital EHR market. While leverage of ~3x EBITDA increases financial risk, the management's projection of near-term accretion and a 3x EBITDA growth target by FY30 could be a positive catalyst for the stock, provided integration risks are managed well.